Amgen Inc. and Merck & Co., Inc. are two of the largest, most established names in global pharmaceuticals, yet they present investors with sharply different risk-and-reward profiles today. Amgen is a biotechnology leader leaning into innovative therapies and biosimilars, while Merck remains anchored by Keytruda, one of the best-selling cancer drugs in history. This stock comparison is relevant for investors weighing growth versus income, evaluating how each company is managing looming patent cliffs, and seeking clarity on relative performance and market positioning. By examining recent financial results, sentiment shifts, and forward-looking catalysts, traders and long-term investors alike can better assess which name is currently positioned more favorably.
AMGN (Amgen) is a global biotechnology company with a diversified portfolio spanning oncology, inflammation, bone health, cardiovascular disease, and rare disease. In recent market activity, Amgen has benefited from broad-based volume growth. For the fourth quarter of 2025, the company reported total revenues of roughly $9.9 billion, up about 9% year over year, with adjusted earnings per share (EPS) that beat consensus estimates. Full-year 2025 sales rose approximately 10%, supported by 14 blockbuster products.
Key growth drivers have included Repatha (cholesterol), EVENITY (osteoporosis), and TEZSPIRE (asthma), each growing well above 30% in 2025, along with rapid uptake of newer oncology drug Imdelltra. Management issued 2026 revenue guidance of roughly $37.0 billion to $38.4 billion with adjusted EPS of $21.60 to $23.00, signaling continued growth. Investor sentiment has also been shaped by Amgen's obesity candidate MariTide, now advancing through multiple Phase 3 studies, and by the acceleration of its biosimilar business. The primary overhang remains biosimilar erosion of Prolia and Xgeva following their U.S. patent expirations in early 2025.
MRK (Merck & Co.) is a diversified pharmaceutical and animal-health company whose oncology franchise, led by Keytruda, drives more than half of its pharmaceutical sales. In the fourth quarter of 2025, Merck reported worldwide sales of approximately $16.4 billion, up about 5% year over year, with adjusted EPS of $2.04, a 19% increase. Full-year 2025 revenue reached about $65.0 billion, a modest 1% increase.
Merck's growth is increasingly reliant on newer products. Winrevair (pulmonary arterial hypertension) and Capvaxive (pneumococcal vaccine) have posted strong early launches, while the subcutaneous formulation Keytruda Qlex extends franchise protection. Offsetting these gains, Gardasil/Gardasil 9 sales have fallen sharply on weaker demand in China. Merck's 2026 guidance — revenue of $65.5 billion to $67.0 billion but adjusted EPS declining to $5.00–$5.15 due to a large one-time charge tied to the roughly $9.2 billion Cidara Therapeutics acquisition — has pressured near-term sentiment. Analysts have nonetheless raised targets recently, citing a catalyst-rich pipeline and progress toward filling the post-Keytruda gap.
For traders seeking an objective, data-driven view of stocks like AMGN and MRK, Tickeron's Trending AI Robots page offers a curated look at automated trading strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker universes — from short-term momentum models to longer-horizon trend-following systems. Browsing the Trending AI Robots section can help investors see which automated approaches are currently gaining traction and how they are positioning across the pharmaceutical sector.
The two companies diverge most clearly on growth trajectory and near-term earnings visibility. Amgen's business model leans on high-growth biologics and biosimilars, and its 2026 guidance implies continued top-line and bottom-line expansion. Merck, by contrast, is a larger, more diversified enterprise spanning pharmaceuticals, vaccines, and animal health, but its 2026 adjusted EPS is expected to decline materially because of acquisition accounting.
Risk profiles also differ. Amgen faces accelerating biosimilar competition for Prolia and Xgeva, yet newer products are growing fast enough to partially offset that erosion. Merck's central challenge is concentration: Keytruda's 2028 loss of exclusivity (LOE) leaves a large revenue gap to fill, and Gardasil's China weakness compounds the pressure. Merck counters with a deeper late-stage pipeline and strategic mergers and acquisitions (M&A), while Amgen's MariTide obesity program represents a higher-upside but still-unproven catalyst. From a market positioning standpoint, Amgen has shown more consistent relative performance and margin strength in recent months, whereas Merck's stock has rallied on analyst upgrades despite softer forward earnings guidance.
Based on observable factors — including revenue momentum, earnings consistency, forward guidance, and relative trend strength — Tickeron's AI would currently lean toward AMGN over MRK. Amgen's combination of double-digit sales growth, sustained operating margins, and a catalyst-rich pipeline offers a more favorable trend profile than Merck's mix of flat-to-modest revenue growth and a near-term earnings reset. Merck's higher dividend yield and diversified portfolio remain strengths, but the probabilistic balance of momentum and positioning currently tilts in Amgen's favor. This assessment reflects relative positioning rather than a definitive outcome and may shift as new clinical data and earnings results emerge.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 36 cases where AMGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 67%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 147 of 271 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The 10-day RSI Indicator for AMGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 22 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMGN as a result. In 29 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 38%.
The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 19 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 41%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.297) is normal, around the industry mean (-1.421). P/E Ratio (28.386) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
MRK moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend. In 33 of 49 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 67%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 46 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for MRK turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 27 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on November 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
The Aroon Indicator for MRK entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 33 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. MRK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.633) is normal, around the industry mean (-1.421). MRK's P/E Ratio (116.452) is considerably higher than the industry average of (21.700). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
AMGN | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 4 | 33 | |
SMR RATING 1..100 | 15 | 79 | |
PRICE GROWTH RATING 1..100 | 40 | 50 | |
P/E GROWTH RATING 1..100 | 35 | 1 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (79) in the Biotechnology industry is in the same range as MRK (88) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to MRK’s over the last 12 months.
AMGN's Profit vs Risk Rating (4) in the Biotechnology industry is in the same range as MRK (33) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to MRK’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is somewhat better than the same rating for MRK (79) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than MRK’s over the last 12 months.
AMGN's Price Growth Rating (40) in the Biotechnology industry is in the same range as MRK (50) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to MRK’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMGN (35) in the Biotechnology industry. This means that MRK’s stock grew somewhat faster than AMGN’s over the last 12 months.
| AMGN | MRK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 47% | 3 days ago 80% |
| Stochastic ODDS (%) | 3 days ago 60% | 3 days ago 67% |
| Momentum ODDS (%) | 3 days ago 38% | 3 days ago 55% |
| MACD ODDS (%) | 3 days ago 41% | 3 days ago 54% |
| TrendWeek ODDS (%) | 3 days ago 50% | 3 days ago 48% |
| TrendMonth ODDS (%) | 3 days ago 48% | 3 days ago 43% |
| Advances ODDS (%) | 14 days ago 62% | 24 days ago 57% |
| Declines ODDS (%) | 3 days ago 46% | 4 days ago 51% |
| BollingerBands ODDS (%) | 3 days ago 67% | 3 days ago 66% |
| Aroon ODDS (%) | 3 days ago 54% | 3 days ago 45% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 2 FA rating(s) are green while MRK’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).
AMGN (@Pharmaceuticals: Major) experienced а -5.91% price change this week, while MRK (@Pharmaceuticals: Major) price change was -9.50% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -12.82%. For the same industry, the average monthly price growth was -9.89%, and the average quarterly price growth was -5.74%.
AMGN is expected to report earnings on Feb 09, 2027.
MRK is expected to report earnings on Feb 02, 2027.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -0.15% | ||
| PFE - AMGN | 51% Loosely correlated | -0.51% | ||
| GILD - AMGN | 48% Loosely correlated | -0.06% | ||
| ABBV - AMGN | 48% Loosely correlated | +0.94% | ||
| BIIB - AMGN | 47% Loosely correlated | +1.00% | ||
| MRK - AMGN | 47% Loosely correlated | +0.69% | ||
More | ||||
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.